Inflammatory bowel disease is a chronic, immune-mediated condition characterized by relapsing inflammation of the gastrointestinal tract. The disease results from complex interactions between genetic susceptibility, immune dysregulation, environmental factors, and the gut microbiome. Advances in molecular biology and immunology have transformed understanding of disease mechanisms, leading to the development of targeted biologic and small-molecule therapies. Modern management emphasizes early diagnosis, risk stratification, and treat-to-target approaches focused on achieving deep remission and mucosal healing. Non-invasive biomarkers, advanced imaging, and endoscopic monitoring have improved disease assessment and therapeutic decision-making. Multidisciplinary care addressing nutrition, mental health, and long-term complications is increasingly recognized as essential. This topic explores evolving concepts in disease pathogenesis, emerging therapeutic strategies, personalized medicine, and long-term disease monitoring aimed at improving quality of life and clinical outcomes for patients with inflammatory bowel disease.